Paradigm Biopharmaceuticals Ltd. has released a press release.
Appendix 4E and 2026 Annual Report
Earlier from Paradigm Biopharmaceuticals
- June 2026 Quarterly Activities Report & Appendix 4C
- Paradigm Receives $5.75m R&D Tax Incentive Refund
- Drawdown of Tranche 4 under the Convertible Note Facility
- PAR Completes Enrolment in Pivotal Phase 3